Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell

Joe Taylor1, Alison M Yeomans1, Graham Packham1

  • 1Cancer Research UK Centre, Cancer Sciences, Faculty of Medicine, University of Southampton, SO16 6YD Southampton, United Kingdom.

Insights

Targeting mRNA translation, a key cancer cell process, offers a promising new therapy. Inhibiting translation initiation factors shows potential for novel anti-tumor drugs in mature B-cell neoplasms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cancer development involves dysregulated mRNA translation, increasing protein synthesis and oncoprotein production.
  • Targeting mRNA translation presents a novel therapeutic strategy for cancer treatment.
  • Mature B-cell neoplasms like CLL, FL, and DLBCL exhibit altered mRNA translation.

Purpose of the Study:

  • To review the dysregulation of mRNA translation initiation in mature B-cell neoplasms.
  • To explore mechanisms linking genetic alterations and the tumor microenvironment to altered mRNA translation.
  • To summarize preclinical and clinical progress of drugs targeting translation initiation factors.

Main Methods:

  • Review of current literature on mRNA translation regulation in cancer.
  • Analysis of mechanisms of mRNA translation dysregulation in B-cell malignancies.
  • Evaluation of preclinical data for drugs targeting eukaryotic initiation factors.

Main Results:

  • Dysregulation of mRNA translation is a hallmark of cancer, particularly in mature B-cell neoplasms.
  • Genetic alterations and the tumor microenvironment significantly impact mRNA translation in malignant B cells.
  • Preclinical studies demonstrate the efficacy of targeting eukaryotic initiation factors.

Conclusions:

  • Inhibition of mRNA translation initiation factors is a promising strategy for novel targeted cancer therapies.
  • Further clinical development of these targeted agents is warranted for B-cell malignancies.
  • Understanding translation regulation provides new avenues for anti-cancer drug discovery.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.6K
Initiation of Translation02:33

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
37.2K
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
71.7K